|
Curis Inc
CRIS's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Curis Inc growth rates, revenue grew
by 14.09 % in the first quarter of 2025 from the same quarter a year ago.
Ranking at No. 1176
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 12.76 %
Curis Inc net loss decreased from $-12 millions, to $-11 millions in first quarter of 2025,
• More on CRIS's Growth
|
|
Curis Inc realized a net loss in trailing twelve months.
Curis Inc realized cash reduction of $ -1.14 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.64.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.17.
• More on CRIS's Valuation
|
|
|
|
|
Curis Inc realized net loss in trailing twelve months.
Curis Inc realized cash outflow of $ -1.14per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.64.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.17.
• More on CRIS's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com